Citigroup’s Syndax Pharmaceuticals SNDX Stock Holding History

Citigroup’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$701K	Hold	30,000	–	–	﹤0.01%	3347
2025 Q4	$630K	Buy	+30,000	New	+$523K	﹤0.01%	3445
2025 Q3	–	Sell	-58,300	Closed	-$546K	–	6304
2025 Q2	$546K	Hold	58,300	–	–	﹤0.01%	3574
2025 Q1	$716K	Buy	+58,300	New	+$822K	﹤0.01%	3476
2023 Q2	–	Sell	-29,900	Closed	-$631K	–	5715
2023 Q1	$631K	Buy	+29,900	New	+$744K	﹤0.01%	2943

Other funds holding SNDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Citigroup's SNDX Position: Q1 2026 in Review

Citigroup reduced its Syndax Pharmaceuticals (SNDX) stake by 14% in Q1 2026, selling an estimated $74.1K and leaving 20,332 shares worth $475K. The position accounts for ﹤0.01% of the portfolio, ranked #3581.

Citigroup first reported a position in SNDX in Q2 2016 and has held it in 39 quarters since. The position peaked at $12.8M in Q3 2022. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

Citigroup held 20,332 shares of Syndax Pharmaceuticals worth $475K as of Q1 2026.
Citigroup sold 3,409 Syndax Pharmaceuticals shares in Q1 2026, an estimated $74.1K.
Syndax Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3581 holding.
Citigroup first reported a position in Syndax Pharmaceuticals in Q2 2016 and has held it in 39 quarters since.
Citigroup's Syndax Pharmaceuticals position peaked at $12.8M in Q3 2022.
246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.